Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medicus Pharma Ltd ( (MDCX) ) has shared an update.
On September 12, 2025, Medicus Pharma Ltd. announced that its Chief Financial Officer, James Quinlan, will be taking a medical leave of absence. In response, Carolyn Bonner has been appointed as the acting CFO while continuing her role as President of the company, which she has held since September 2023. Ms. Bonner brings extensive experience from her previous roles in the healthcare and biotech industries, including her leadership positions at Parkway Clinical Laboratories and Rosetta Genomics. Her dual role is not accompanied by additional compensation or formal agreements, and there are no familial or reportable transactions involving her and the company.
The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.
Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Average Trading Volume: 411,673
Technical Sentiment Signal: Sell
Current Market Cap: $40.09M
See more insights into MDCX stock on TipRanks’ Stock Analysis page.